ProCE Banner Activity

Ruxolitinib vs Best Available Therapy in Myelofibrosis: A 5-Year Follow-up of COMFORT-II

Slideset Download
Conference Coverage
Durable efficacy with reductions in bone marrow fibrosis, JAK2 V617F allele burden, and risk of death sustained over longer-term use of ruxolitinib.

Released: December 09, 2015

Expiration: December 07, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen